Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EHP 102

Next Previous
Search
Drug Profile

EHP 102

Alternative Names: EHP-102; VCE 003.2

Latest Information Update: 28 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aphios Corporation; Emerald Health Sciences; Universidad Nacional de Cordoba
  • Developer Emerald Health Sciences
  • Class Antiparkinsonians; Cannabinoids; Neuroprotectants; Quinones; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists; PPAR alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease
  • No development reported Huntington's disease

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for preclinical development in Huntington's-disease in USA (PO)
  • 17 Nov 2022 Preclinical trials in Parkinson's disease in Spain (PO)
  • 13 Oct 2022 Emerald Health Pharmaceuticals announces intention to submit IND for Parkinson’s disease and Huntington’s disease

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top